Review: Recent advances in argatroban-warfarin transition in patients with heparin-induced thrombocytopenia

Ziad Taimeh, Babette Weksler

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Heparin-induced thrombocytopenia is a devastating, life-threatening, immune-mediated complication of therapy with unfractionated heparin, and less frequently, with low molecular weight heparin. Direct thrombin inhibitors are now standard therapy for the prevention of thrombosis in heparin-induced thrombocytopenia. Argatroban, a small synthetic molecule that inhibits thrombin at its active site, is increasingly used as the direct thrombin inhibitors of choice. Transition to longer term oral anticoagulation needs to be instituted after the platelet count has risen, because of the persistent risk of thrombosis. Although guidelines available in the literature outline the management of heparin-induced thrombocytopenia, they are not presented in a concise and comprehensive manner easily followed by physicians. This article reviews current recommendations, relevant studies, and clinical management trials carried out on patients with heparin-induced thrombocytopenia and provides updated, detailed guidelines for treatment of heparin-induced thrombocytopenia with emphasis on a key part of the management, the argatrobang-warfarin transition.

Original languageEnglish (US)
Pages (from-to)5-12
Number of pages8
JournalClinical and Applied Thrombosis/Hemostasis
Issue number1
StatePublished - Feb 2010

Bibliographical note

Copyright 2010 Elsevier B.V., All rights reserved.


  • Argatroban
  • Direct thrombin inhibitor
  • Heparin-induced thrombocytopenia
  • Unfractionated heparin
  • Warfarin


Dive into the research topics of 'Review: Recent advances in argatroban-warfarin transition in patients with heparin-induced thrombocytopenia'. Together they form a unique fingerprint.

Cite this